Compass Pathways (NASDAQ:CMPS – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Monday, Wall Street Zen reports.
A number of other equities analysts also recently weighed in on CMPS. BTIG Research reaffirmed a “buy” rating and issued a $25.00 target price on shares of Compass Pathways in a research note on Tuesday, November 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Pathways in a research note on Thursday, October 15th. Royal Bank Of Canada reissued an “outperform” rating on shares of Compass Pathways in a research note on Wednesday, November 4th. Morgan Stanley raised their price target on shares of Compass Pathways from $17.00 to $18.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Compass Pathways in a research report on Monday, November 9th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Compass Pathways has an average rating of “Moderate Buy” and a consensus target price of $23.14.
View Our Latest Stock Report on CMPS
Compass Pathways Price Performance
Compass Pathways (NASDAQ:CMPS – Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.08. On average, research analysts expect that Compass Pathways will post -0.78 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Compass Pathways
Institutional investors and hedge funds have recently modified their holdings of the business. Candriam S.C.A. boosted its stake in Compass Pathways by 18.6% in the third quarter. Candriam S.C.A. now owns 1,510,695 shares of the company’s stock valued at $18,862,000 after acquiring an additional 236,417 shares during the last quarter. Creek Drive Management Group LLC grew its holdings in Compass Pathways by 91.9% during the 3rd quarter. Creek Drive Management Group LLC now owns 1,328,000 shares of the company’s stock worth $16,520,000 after acquiring an additional 636,000 shares during the period. Eagle Health Investments LP raised its position in shares of Compass Pathways by 35.6% during the 1st quarter. Eagle Health Investments LP now owns 2,060,427 shares of the company’s stock valued at $11,394,000 after acquiring an additional 541,039 shares during the last quarter. CenterBook Partners LP raised its position in shares of Compass Pathways by 454.1% during the 3rd quarter. CenterBook Partners LP now owns 695,943 shares of the company’s stock valued at $8,658,000 after acquiring an additional 570,349 shares during the last quarter. Finally, Orbimed Advisors LLC bought a new stake in shares of Compass Pathways during the 1st quarter valued at $6,363,000. 46.19% of the stock is owned by institutional investors.
Compass Pathways Company Profile
Compass Pathways plc is a biotechnology company developing treatments for mental health conditions. Founded in 2016 by George Goldsmith and Ekaterina Malievskaia, the company is focused on advancing psychedelic-based therapies through clinical research. Its lead investigational product, COMP360, is a synthetic formulation of psilocybin being studied alongside psychological support. Compass is evaluating COMP360 primarily as a potential treatment for treatment-resistant depression and has also explored its use for other mental health conditions, including post-traumatic stress disorder.
Further Reading
- Five stocks we like better than Compass Pathways
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Compass Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Pathways and related companies with MarketBeat.com's FREE daily email newsletter.
